Tuesday, July 23, 2019

Journals on Medical Research - BJSTR Journal

Abstract

The use of #repetitive transcranial magnetic stimulation has grown over the last ten years since the FDA approval in 2008 and has been also included in NICE UK as an optional treatment [1] and it is likely to continue to grow in terms of its use as it has been showing the following promising findings: good results in a variety of #neuropsychiatric disorders such as #anxiety [2], obsessive compulsive disorder [3], auditory hallucinations [4], PTSD [5], tinnitus [6], migraine [7], post-stroke rehabilitation [8] etc. It also provides a neuroprotective mechanism [9] which may enhance cognitive function. We would like to present a 52 year old lady with a history of recurrent depressive disorder, with the current episode lasting over two years. She had a history of recurrent depressive disorder since she was 17 years old. Her current presentation was with decreased sleep, decreased appetite, lack of concentration, lack of energy, low mood and anhedonia as she could not enjoy anything in her life anymore. She was partially functioning socially and with keeping up a part time job. She was on Lamictal (Lamotrigine) 50 mg BD, Efexor XR (Venlafaxine) 150mg daily, Seroquel (Quetiapine) 50mg nocte and #Wellbultrin (Buproprion) 150mg daily when she came to our clinic. She was previously tried on higher doses of Efexor XR (Venlafaxine) with no response from her clinical history. Also 6 months prior to attending to our clinic she received a total of 8 sessions of ECT twice weekly with some improvement in her mental state at the time but not with a sustainable effect and did not lead to a full recovery. She had a medication review and Lamotrigine was stopped to have a better effect with rTMS. Subsequently we did start a 5 times per week rTMS course over 6 weeks with a magpro (Magventure) stimulator, theta burst pulses were given for 3 minutes in each session, on the left DLPFC, a total of thirty sessions. The patient went into a full recovery of her depressive episode one week post treatment completion. We also stopped Buproprion, Quetiapine and during treatment we also increase #Venlafaxine XR to 150mg BD. She did not present with any side effects from the rTMS therapy.

For more articles on BJSTR Journal please click on https://biomedres.us/

For more Medical Research Articles on BJSTR


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Nanomedicine and Nano Formulations for Neurodegenerative Diseases

  Nanomedicine and Nano Formulations for Neurodegenerative Diseases Introduction Neurodegenerative diseases are characterized by the progres...